CHILDRENS MERCY HOSPITAL
- Type
- Teaching hospital
- Where
- Kansas City, MO
- Medicare CCN
- 263302
- Received
- $2,272,920 in 504 records, 2020 ($17,457 general, $2,255,463 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE CHILDRENS MERCY HOSPITAL CORPORATION Fuzzy (name and state)
- Federal award recipient: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
- Nonprofit: CHILDRENS MERCY HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 25 | $17,457 |
| 2020 | Research payment | 479 | $2,255,463 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 479 | $2,255,463 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $12,227 |
| Gift | 20 | $3,530 |
| Space rental or facility fees (teaching hospital only) | 3 | $1,700 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $859 | Research payment | Cash or cash equivalent | TCH2019MRIPR785Mazur | 2020 | |
| 2020-12-31 | Stryker Corporation | $525 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca UK Limited | $46 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2020 |
| 2020-12-31 | Aimmune Therapeutics, Inc. | $18 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $0 | Gift | In-kind items and services | Device, Zimmer Biomet Instruments and Implants | 2020 | |
| 2020-12-29 | Merck Sharp & Dohme LLC | $5,405 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-12-28 | Aimmune Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-24 | Amgen Inc. | $6,050 | Research payment | Cash or cash equivalent | Kyprolis Drug, Oncology | Kyprolis (CFZ) Ph1/2 Pediatric ALL | 2020 |
| 2020-12-24 | Amgen Inc. | $692 | Research payment | Cash or cash equivalent | Parsabiv Drug, Nephrology | Pediatric Multi-Dose | 2020 |
| 2020-12-23 | Edwards Lifesciences Corporation | $8,745 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2020 |
| 2020-12-23 | Edwards Lifesciences Corporation | $4,569 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $633 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-12-22 | JAZZ PHARMACEUTICALS INC. | $180,000 | Research payment | Cash or cash equivalent | DEFITELIO Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR | 2020 |
| 2020-12-22 | Novo Nordisk AS | $200 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2020 |
| 2020-12-21 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,049 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT440-038_3702_01 | 2020 |
| 2020-12-18 | SANOFI US SERVICES INC. | $296 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) | 2020 |
| 2020-12-17 | ABBVIE INC. | $466 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-12-17 | Boehringer Ingelheim Italia S.p.A. | $212 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-12-15 | Travere Therapeutics, Inc. | $1,150 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-12-15 | Travere Therapeutics, Inc. | $920 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-12-14 | BioFire Diagnostics, LLC | $195 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-12-09 | BioFire Diagnostics, LLC | $242 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire RST Study | 2020 |
| 2020-12-08 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,049 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT440-038_3702_01 | 2020 |
| 2020-12-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-08 | Incyte Corporation | $12 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-12-07 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,190 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-12-03 | Edwards Lifesciences Corporation | $53,763 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2020 |
| 2020-12-03 | Genentech, Inc. | $7,705 | Research payment | Cash or cash equivalent | Mircera Biological, Hematology | CONFIRMATORY STUDY | 2020 |
| 2020-12-03 | BioFire Diagnostics, LLC | $1,248 | Research payment | In-kind items and services | SpotFire System Device, Clinical Diagnostics | SpotFire RST Study | 2020 |
| 2020-12-02 | IBSA Pharma Inc. | $9,100 | Research payment | Cash or cash equivalent | Tirosint Drug, Endocrinology | Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients | 2020 |
| 2020-12-02 | Gilead Sciences, Inc. | $718 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-12-01 | Travere Therapeutics, Inc. | $293 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-12-01 | Boehringer Ingelheim Italia S.p.A. | $122 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-12-01 | Travere Therapeutics, Inc. | $26 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-11-27 | Edwards Lifesciences Corporation | $20,293 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2020 |
| 2020-11-25 | Novo Nordisk AS | $1,950 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2020 |
| 2020-11-25 | Novo Nordisk AS | $797 | Research payment | Cash or cash equivalent | Sogroya Biological, Growth Hormone | NN8640-4263 | 2020 |
| 2020-11-25 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-24 | Mallinckrodt Hospital Products Inc. | $1,000 | Research payment | Cash or cash equivalent | INOMAX Drug, CRITICAL CARE | REGISTRY EVALUATING PREMATURE AND TERM-NEAR-TERM NEONATES WITH PULMONARY HYPERTENSION RECEIVING INHALED NITRIC OXIDE | 2020 |
| 2020-11-20 | GLOBAL BLOOD THERAPEUTICS, INC. | $3,665 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT440-038_3702_01 | 2020 |
| 2020-11-19 | Dexcom, Inc. | $14,562 | Research payment | Cash or cash equivalent | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2020 |
| 2020-11-19 | Travere Therapeutics, Inc. | $400 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-11-19 | Merck Sharp & Dohme LLC | $200 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $2,312 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-11-18 | Travere Therapeutics, Inc. | $1,069 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-11-18 | Travere Therapeutics, Inc. | $960 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-11-18 | Travere Therapeutics, Inc. | $960 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-11-18 | Travere Therapeutics, Inc. | $663 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-11-18 | Gilead Sciences, Inc. | $633 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-11-17 | Merck Sharp & Dohme LLC | $3,100 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, To | 2020 |
| 2020-11-16 | Gilead Sciences, Inc. | $60 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-11-11 | Gilead Sciences, Inc. | $1,000 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-11-11 | Merck Sharp & Dohme LLC | $93 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-11 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-11 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-11 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-10 | SANOFI PASTEUR INC. | $1,955 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-11-10 | Alexion Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-11-06 | Novo Nordisk AS | $46 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-11-05 | Abbott Laboratories | $655 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | REDCHiP: Reducing Emotional Distress for Childhood Hypoglycemia in Parents | 2020 |
| 2020-11-05 | Abbott Laboratories | $518 | Research payment | In-kind items and services | FreeStyle Lite system Device, Diabetes Care | REDCHiP: Reducing Emotional Distress for Childhood Hypoglycemia in Parents | 2020 |
| 2020-11-03 | Merck Sharp & Dohme LLC | $203 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-02 | Travere Therapeutics, Inc. | $418 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-11-01 | Boehringer Ingelheim Italia S.p.A. | $119 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-10-29 | GLOBAL BLOOD THERAPEUTICS, INC. | $4,757 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-10-29 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,341 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-10-29 | PFIZER INC. | $1,068 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-27 | Novo Nordisk AS | $2,233 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-10-27 | Travere Therapeutics, Inc. | $95 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-10-27 | Boehringer Ingelheim Italia S.p.A. | $3 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-26 | Alexion Pharmaceuticals, Inc. | $233 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-10-23 | Amgen Inc. | $14,259 | Research payment | Cash or cash equivalent | Kyprolis Drug, Oncology | 4020 - CFZ Ph1 Pediatric ALL (CFZ 008) | 2020 |
| 2020-10-23 | Dexcom, Inc. | $9,229 | Research payment | Cash or cash equivalent | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2020 |
| 2020-10-22 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or | 2020 |
| 2020-10-22 | Novo Nordisk AS | $186 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-10-21 | BioFire Diagnostics, LLC | $10,547 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-10-19 | Travere Therapeutics, Inc. | $410 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-10-19 | Travere Therapeutics, Inc. | $410 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-10-19 | Travere Therapeutics, Inc. | $130 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-10-19 | Travere Therapeutics, Inc. | $118 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-10-17 | PFIZER INC. | $262 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-10-16 | Travere Therapeutics, Inc. | $2,218 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-10-13 | PFIZER INC. | $3,296 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-13 | PFIZER INC. | $1,068 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-13 | PFIZER INC. | $345 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-13 | PFIZER INC. | $281 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-13 | PFIZER INC. | $99 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-13 | PFIZER INC. | $66 | Research payment | In-kind items and services | IBRANCE Drug, ONCOLOGY | AN OPEN LABEL PHASE 12 CLINICAL STUDY OF PD0332991 IN COMBINATION WITH BACKBONE CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH | 2020 |
| 2020-10-08 | BioFire Diagnostics, LLC | $3,403 | Research payment | Cash or cash equivalent | Gastrointestinal Panel Kit (RFIT-ASY-0116) Device, Clinical Diagnostics | Etiology and prevalence of acute gastroenteritis (AGE) in US children | 2020 |
| 2020-10-01 | BioFire Diagnostics, LLC | $40,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-10-01 | PFIZER INC. | $262 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE V | 2020 |
| 2020-10-01 | Boehringer Ingelheim Italia S.p.A. | $120 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-09-29 | Novo Nordisk AS | $797 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-09-28 | ABBVIE INC. | $3,791 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-09-28 | PFIZER INC. | $2,700 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-09-28 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED MULTICENTER OPENLABEL CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF | 2020 | |
| 2020-09-28 | Genentech, Inc. | $59 | Research payment | Cash or cash equivalent | Mircera Biological, Hematology | CONFIRMATORY STUDY | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $4,258 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-24 | Amgen Inc. | $308 | Research payment | In-kind items and services | Parsabiv Drug, Nephrology | Pediatric Multi-Dose | 2020 |
| 2020-09-24 | LEICA MICROSYSTEMS INC. | $48 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-09-23 | Gilead Sciences, Inc. | $969 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-09-22 | JAZZ PHARMACEUTICALS INC. | $127,029 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-09-18 | Boehringer Ingelheim Italia S.p.A. | $77 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-09-18 | Boehringer Ingelheim Italia S.p.A. | $53 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-09-17 | Dexcom, Inc. | $3,076 | Research payment | Cash or cash equivalent | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2020 |
| 2020-09-17 | Travere Therapeutics, Inc. | $715 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-09-16 | Travere Therapeutics, Inc. | $1,168 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-16 | Travere Therapeutics, Inc. | $1,168 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-16 | Travere Therapeutics, Inc. | $948 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-16 | Travere Therapeutics, Inc. | $948 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-16 | Travere Therapeutics, Inc. | $805 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-16 | Travere Therapeutics, Inc. | $220 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-09-15 | Merck Sharp & Dohme LLC | $406 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-15 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-11 | BioFire Diagnostics, LLC | $4,689 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-09-09 | Genentech, Inc. | $8,321 | Research payment | Cash or cash equivalent | Mircera Biological, Hematology | CONFIRMATORY STUDY | 2020 |
| 2020-09-07 | GLOBAL BLOOD THERAPEUTICS, INC. | $2,098 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT440-038_3702_01 | 2020 |
| 2020-09-02 | Gilead Sciences, Inc. | $718 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-09-02 | Gilead Sciences, Inc. | $585 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $93 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $74 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-01 | Boehringer Ingelheim Italia S.p.A. | $122 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-09-01 | Travere Therapeutics, Inc. | $26 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $2,033 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-08-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,799 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2020 |
| 2020-08-27 | ABBVIE INC. | $4,815 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-08-26 | Boehringer Ingelheim Italia S.p.A. | $125 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-08-25 | Novo Nordisk AS | $2,741 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-08-22 | Dexcom, Inc. | $8,204 | Research payment | Cash or cash equivalent | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2020 |
| 2020-08-20 | Merck Sharp & Dohme LLC | $11,166 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $1,439 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-08-17 | Travere Therapeutics, Inc. | $1,329 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-08-17 | Travere Therapeutics, Inc. | $1,063 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2020 | |
| 2020-08-11 | Aimmune Therapeutics, Inc. | $290 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-08-11 | Aimmune Therapeutics, Inc. | $290 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-08-11 | Aimmune Therapeutics, Inc. | $290 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-08-11 | Aimmune Therapeutics, Inc. | $287 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-08-10 | Amgen Inc. | $0 | Research payment | In-kind items and services | Aimovig Biological, Neuroscience | Ph3 Pediatric CM Study. | 2020 |
| 2020-08-06 | Edwards Lifesciences Corporation | $6,173 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | ALTERRA Early Feasibility (2016-04) | 2020 |
| 2020-08-06 | ABBVIE INC. | $1,199 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | P12-792 | 2020 |
| 2020-08-06 | VIVUS LLC | $403 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis | 2020 |
| 2020-08-01 | Boehringer Ingelheim Italia S.p.A. | $121 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-07-31 | Merck Sharp & Dohme LLC | $18,696 | Research payment | In-kind items and services | NEXPLANON Drug, WOMENS HEALTH | Intervention to Facilitate Contraception Provision by Pediatric Hospitalists A Feasibility Study | 2020 |
| 2020-07-31 | Merck Sharp & Dohme LLC | $975 | Research payment | In-kind items and services | NUVARING Drug, WOMENS HEALTH | Intervention to Facilitate Contraception Provision by Pediatric Hospitalists A Feasibility Study | 2020 |
| 2020-07-30 | Edwards Lifesciences Corporation | $4,000 | Research payment | Cash or cash equivalent | COMPASSION Study 2006-09 | 2020 | |
| 2020-07-30 | Edwards Lifesciences Corporation | $569 | Research payment | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | COMPASSION S3 2015-01 | 2020 |
| 2020-07-30 | GLOBAL BLOOD THERAPEUTICS, INC. | $330 | Research payment | Cash or cash equivalent | OXBRYTA Drug, SICKLE CELL DISEASE | GBT_GBT_PEDIATRIC_440-007_2926_01 | 2020 |
| 2020-07-29 | ABBVIE INC. | $1,556 | Research payment | Cash or cash equivalent | LUPRON DEPOT Drug, ENDOCRINOLOGY | M16-904 | 2020 |
| 2020-07-28 | BioFire Diagnostics, LLC | $9,305 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $863 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-28 | Novo Nordisk AS | $720 | Research payment | Cash or cash equivalent | NN8640-4263 | 2020 | |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $235 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-28 | Alexion Pharmaceuticals, Inc. | $15 | Research payment | Cash or cash equivalent | Strensiq Drug, Endocrinology | An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP) | 2020 |
| 2020-07-27 | Merck Sharp & Dohme LLC | $372 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-23 | Merck Sharp & Dohme LLC | $4,696 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-23 | AMAG Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | FERAHEME Drug, PARENTERAL IRON REPLACEMENT | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY (COMPARED TO IRON SUCROSE), EFFICACY AND PHA | 2020 |
| 2020-07-22 | Merck Sharp & Dohme LLC | $25,556 | Research payment | Cash or cash equivalent | PRIMAXIN Drug, INFECTIOUS DISEASE | Comparative In Vitro Activity of Imipenem-Relebactam against Pediatric Drug-Resistant Gram Negative Isolates from three | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $1,142 | Research payment | Cash or cash equivalent | Vemlidy Drug, HBV | A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Ala | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $1,000 | Research payment | Cash or cash equivalent | Epclusa Drug, HCV | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $633 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2020 |
| 2020-07-22 | United Therapeutics Corporation | $500 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | INTRAVENOUS REMODULIN (TREPROSTINIL) AS ADD-ON THERAPY FOR THE TREATMENT OF PERSISTENT PULMONARY HYPERTENSION OF THE NEW | 2020 |
| 2020-07-22 | Eli Lilly and Company | $251 | Research payment | In-kind items and services | A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | 2020 | |
| 2020-07-22 | Eli Lilly and Company | $123 | Research payment | In-kind items and services | PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREA | 2020 | |
| 2020-07-21 | SANOFI PASTEUR INC. | $5,750 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-07-20 | Amgen Inc. | $1,680 | Research payment | In-kind items and services | Parsabiv Drug, Nephrology | AMG 416 Pediatric | 2020 |
| 2020-07-20 | Travere Therapeutics, Inc. | $1,498 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-07-20 | Travere Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-07-20 | Travere Therapeutics, Inc. | $95 | Research payment | Cash or cash equivalent | DUET | 2020 | |
| 2020-07-16 | Genentech, Inc. | $8,112 | Research payment | Cash or cash equivalent | Pegasys Biological, Virology & Specialty Care | PEG LAMIVUDINE ENTECAVIR TX IN CHILDREN WITH CHRONIC HBV | 2020 |
| 2020-07-16 | Dexcom, Inc. | $1,640 | Research payment | Cash or cash equivalent | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | POST APPROVAL STUDY FOR NON-ADJUNCTIVE USE OF DEXCOM G5 AND G6 CGM SYSTEM FOR DIABETES MANAGEMENT (COACH) | 2020 |
| 2020-07-16 | Merck Sharp & Dohme LLC | $187 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-16 | Merck Sharp & Dohme LLC | $60 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-16 | Merck Sharp & Dohme LLC | $49 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-16 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-16 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-07-15 | Gilead Sciences, Inc. | $1,150 | Research payment | Cash or cash equivalent | Epclusa Drug, HCV | A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir | 2020 |
| 2020-07-09 | Amgen Inc. | $46 | Research payment | In-kind items and services | Aimovig Biological, Neuroscience | Phase P3 Pediatric Study (EM). | 2020 |
| 2020-07-07 | Boehringer Ingelheim Italia S.p.A. | $69 | Research payment | In-kind items and services | OFEV Drug, RESPIRATORY | Pediatric ILD program | 2020 |
| 2020-07-01 | BioFire Diagnostics, LLC | $40,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray GI STA Pivotal Study | 2020 |
| 2020-07-01 | Aimmune Therapeutics, Inc. | $3,786 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
The latest 200 records of 504.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kansas City, MO, county Jackson County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Kansas City, MO | County Jackson County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 510,612 | 719,976 | 6,191,814 |
| Population, 2020 census P1 | 508,090 | 717,204 | 6,154,913 |
| Median age B01002 | 35.8 | 37.0 | 39.0 |
| Under 18 B01001 | 22.5% | 23.3% | 22.3% |
| 65 and over B01001 | 14.3% | 15.9% | 17.9% |
| Households B11001 | 221,979 | 306,798 | 2,508,227 |
| Foreign born B05002 | 8.6% | 6.6% | 4.5% |
| Median household income B19013 | $69,166 | $68,577 | $70,702 |
| Median family income B19113 | $92,934 | $90,585 | $91,360 |
| Per capita income B19301 | $41,393 | $39,559 | $39,695 |
| Poverty rate B17001 | 14.6% | 14.1% | 12.6% |
| Unemployment rate B23025 | 4.4% | 4.7% | 4.0% |
| Civilian labor force B23025 | 279,828 | 381,433 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.7 | 23.4 | 23.5 |
| Bachelor's degree or higher B15003 | 38.4% | 34.0% | 32.4% |
| Housing units B25001 | 245,346 | 336,288 | 2,825,287 |
| Owner-occupied B25003 | 55.4% | 59.1% | 68.1% |
| Renters B25003 | 44.6% | 40.9% | 31.9% |
| Median home value B25077 | $242,900 | $230,500 | $230,300 |
| Median gross rent B25064 | $1,238 | $1,197 | $1,033 |
| White, not Hispanic B03002 | 54.0% | 59.3% | 76.3% |
| Black B03002 | 25.2% | 22.0% | 10.9% |
| Hispanic or Latino B03002 | 12.5% | 11.4% | 5.2% |
| Asian B03002 | 2.8% | 1.8% | 2.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kansas City, MO.
Comments